Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus adalimumab for refractory Behçet's disease
2017-000845-39Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Behçet's disease (BD) comparing Adalimumab arm with Infliximab arm (2 arms). Primary endpoint: Time to response of major Behçet's manifestations. Started Jun 2021; status: completed.
02
Drugs
adalimumabinfliximab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2017-000845-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000845-39.